Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01205334 : Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
PhasePhase 1/Phase 2
AgesMin: N/A Max: N/A

- Histopathological verification of glioblastoma multiforme (GBM: WHO grade IV) in
remission (Group A) or with active disease (Group B).

- CMV-positive GBM

- CMV seropositive

- Life expectancy 6 weeks or greater

- Karnofsky/Lansky score 50 or greater

- Patient or parent/guardian capable of providing informed consent

- Bilirubin less than 1.5x upper limit of normal, AST less than 3x upper limit of
normal, serum creatinine less than 1.5x normal and Hgb 8.0 g/dL or greater

- Pulse oximetry of 90% or greater on room air

- Sexually active patients must be willing to utilize one of the more effective birth
control methods for 6 months after the CTL infusion. The male partner should use a

- Patients should have been off other investigational antineoplastic therapy for one
month prior to entry in this study.

- Informed consent explained to, understood by and signed by patient/guardian.
Patient/guardian given copy of informed consent.


- Severe intercurrent infection

- Known HIV positivity

- Pregnant or lactating

- History of hypersensitivity reactions to murine protein-containing products.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557